Fig. 4.

Proportion of patients with any dosing interruptions from pooled data of the phase III controlled trials. Data shown are pooled from the two phase III studies, hard-tissue (bunionectomy) and soft tissue (abdominoplasty). The relative risk reduction vs. morphine is shown in the figure. In the hard tissue study, the proportion of patients with any dosing interruptions was low and similar in the oliceridine 0.1 mg and placebo regimens (1.3% and 0% of patients, respectively). The proportions in the 0.35 and 0.5 mg oliceridine treatment regimens were 7.6% and 12.7% of patients, respectively. The proportion in the morphine regimen was 19.7% of patients. In the soft tissue study, the proportion of patients with any dosing interruptions was low and similar in the oliceridine 0.1 mg and placebo regimens (6.5% and 3.6% of patients, respectively). The proportion in the 0.35 and 0.5 mg oliceridine treatment regimens were 21.5% and 22.5% of patients, respectively. The proportion in the morphine regimen was 29.3% of patients